We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oncimmune Holdings Plc | ONC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 14.55 | 08:00:12 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 14.55 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 01/8/2023 14:05 by pugugly Some investors seem unhappy about management changes and dumping - Thoughts? |
Posted at 20/12/2022 07:22 by brummy_git More encouraging contract wins for leading immunodiagnostics firm, Oncimmune.All the news and investor commentary here. www.linkedin.com/pos |
Posted at 06/3/2022 10:15 by itsyou Brummy_git,Thanks for that and the one 2 one earlier in the week. It's a hidden gem, but probably due to investors not understanding the tech, or the RNS content. Even Justin in the last interview, with his FDA comme3nt, highlights a need for the company to do a plain non tech version of the RNS and what their tech does. Maybe some PR also to attract a wider audience before it gets snapped up on the cheap! |
Posted at 19/2/2022 04:42 by 40 fathoms 3 comments in 2 months, I love it. Just confirms what a hidden gem that this is.I am certain that the market does not understand the ImmunoINSIGHTS business and the commercial and medical importance of discovering and validating novel biomarkers, improving disease stratification and understanding disease heterogeneity. Management are not yet explaining this business, its uniqueness and wider strategic importance in a way that allows a majority of investors to grasp the full extent of the opportunity in front of it. I don't think it would be a bad idea to do it in crayons, I almost mean this literally. A couple of slides in a IR preso that are overly simplified and visual would do wonders in my opinion. |
Posted at 09/6/2021 08:10 by homebrewruss Recording and Q&A now available from yesterday |
Posted at 08/6/2021 16:13 by pugugly IMC Useful presentation with useful revene figures - Has been recorded and well worth a listen (imo) if a holder or a potential investor |
Posted at 08/6/2021 10:48 by homebrewruss Latest proactive interviewand ONC also presenting on investor meet later today at 4.30pm |
Posted at 08/6/2021 10:13 by someuwin N+1 SingerTrading update reaffirms positive outlook A comprehensive FY’21 (May Y/E) trading statement touts a strong FY’21 outturn in line with our expectations that shows 8x topline growth, building strength in the ImmunoINSIGHTS service business and sets the tone for future upgrades. We leave estimates unchanged, but believe forecasts are prudently pitched with risk to the upside. Notably Investors should take confidence in that management believes that, eight days into the new financial year and a strong start to FY’22, it has visibility on up to 50% of our current FY’22 ImmunoINSIGHTS revenue estimate (£9.4m) and has used today’s statement to reiterate confidence in meeting expectations and delivering maiden profitability in FY’22. Refreshing our valuation analysis implies an intrinsic value of 271p, we reiterate Oncimmune as a Best Idea for 2021... |
Posted at 28/5/2021 06:43 by someuwin ("Oncimmune" or the "Company")Notice of FY21 Trading Update Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces that it will issue a trading update for the year ended 31 May 2021 on 8 June 2021. Analyst and investor presentations Dr Adam M Hill, Chief Executive Officer and Matthew Hall, Chief Financial Officer will host an online presentation for analysts at 11:30am BST on 8 June 2021. For registration details please contact Alexander Davis of FTI Consulting at Alexander.Davis@ftic Dr Adam M Hill and Matthew Hall will also host a live presentation on Investor Meet Company at 4:30pm BST on 8 June 2021 which will be open to all existing Oncimmune shareholders and potential new investors. Access to Investor Meet Company is free and interested parties are invited to register their attendance on the following link: Investors who already follow Oncimmune Holdings plc on the Investor Meet Company platform will automatically be invited. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am BST the day before the meeting or at any time during the live presentation. |
Posted at 15/2/2021 16:55 by pugugly Presentation now on - Is being recorded - so (imo) well worth as listen if not able to make it now=Investor meet company |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
